Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Mark Giembycz"'
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Externí odkaz:
https://doaj.org/article/4aba11b46c0046c19b923c8d65f0650e
Autor:
Chengcan Yao, David F. Woodward, Yukihiko Sugimoto, Xavier Norel, Shuh Narumiya, Robert L. Jones, Akos Heinemann, Mark Giembycz, Lucie Clapp
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2023
Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [701]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Differences and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f361c7e539c1b737d1fea3aa435f8ba8
https://doi.org/10.2218/gtopdb/f58/2023.1
https://doi.org/10.2218/gtopdb/f58/2023.1
Autor:
Chengcan Yao, David F. Woodward, Mohib Uddin, Yukihiko Sugimoto, Roy Pettipher, Xavier Norel, Shuh Narumiya, Robert L. Jones, Rebecca Hills, Akos Heinemann, Mark Giembycz, Robert A. Coleman, Lucie Clapp, Richard M. Breyer
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2020
Prostanoid receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Prostanoid Receptors [661]) are activated by the endogenous ligands prostaglandins PGD2, PGE1, PGE2 , PGF2α, PGH2, prostacyclin [PGI2] and thromboxane A2. Differences and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9f83a7fcd6abe33007473789ee83ab4e
https://doi.org/10.2218/gtopdb/f58/2020.4
https://doi.org/10.2218/gtopdb/f58/2020.4